For research use only. Not for therapeutic Use.
M109S is a novel small molecule protecting cells from mitochondria-dependent apoptosis both in vitro and in vivo. M109S has the potential to become a research tool for studying cell death mechanisms and to develop therapeutics targeting mitochondria-dependent cell death pathway. M109S has orally bioactivity with excellent brain permeability[1].
M109S (0.1-10000 nM, 24-48 h) inhibits apoptosis induced by Bax as well as Bak[1].
M109S (0-10μM, 4 h) suppresses Staurosporine (HY-15141 STS)-induced apoptosis in MEFs [1].
M109S (0-10μM, 24 h) inhibits Etoposide (HY-13629)-induced apoptosis in Neuro2a cells[1].
M109S (500 nM, 24 h) inhibits Obatoclax (HY-10969A)-induced apoptosis in ARPE19 cells[1].
M109S (500 nM, 48 h) suppresses the conformation change (N-terminal exposure) and mitochondrial translocation of Bax[1].
M109S (1.0 μM, 4h) decreases mitochondrial oxygen consumption and reactive oxygen species, whereas M109S (0.1-1 nM, 4 h) increases glycolysis[1].
M109S (10mg/kg p.o., three time in 48 h) protects the retina from the bright-light-induced photoreceptor death[1].
M109S (1 mg/kg, i.p., i.v., 5 mg/kg, o.p. 10 mg/kg 1 time) is an orally bioactive cell death inhibitor penetrating blood-brain/retina-barrier[1].
| Catalog Number | I040683 |
| CAS Number | 2578300-07-7 |
| Synonyms | N-[(1S)-1-[4-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)phenyl]ethyl]-2,6-dimethylfuro[2,3-d]pyrimidin-4-amine |
| Molecular Formula | C21H21N5O2 |
| Purity | ≥95% |
| InChI | InChI=1S/C21H21N5O2/c1-11-10-17-19(23-13(3)24-21(17)27-11)22-12(2)14-4-8-16(9-5-14)20-25-18(26-28-20)15-6-7-15/h4-5,8-10,12,15H,6-7H2,1-3H3,(H,22,23,24)/t12-/m0/s1 |
| InChIKey | HKRGAACOQSQCIC-LBPRGKRZSA-N |
| SMILES | CC1=CC2=C(N=C(N=C2O1)C)NC(C)C3=CC=C(C=C3)C4=NC(=NO4)C5CC5 |
| Reference | [1]. Mieko Matsuyama, et al. Development of novel cytoprotective small compounds inhibiting mitochondria-dependent cell death. Science 26, 107916, October 20, 2023 |
